{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T12:55:32Z","timestamp":1770987332938,"version":"3.50.1"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2011,2,7]],"date-time":"2011-02-07T00:00:00Z","timestamp":1297036800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BMC Psychiatry"],"published-print":{"date-parts":[[2011,12]]},"DOI":"10.1186\/1471-244x-11-21","type":"journal-article","created":{"date-parts":[[2011,2,8]],"date-time":"2011-02-08T02:15:21Z","timestamp":1297131321000},"source":"Crossref","is-referenced-by-count":26,"title":["Paliperidone ER and oral risperidone in patients with schizophrenia: a comparative database analysis"],"prefix":"10.1186","volume":"11","author":[{"given":"Ibrahim","family":"Turkoz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cynthia A","family":"Bossie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Pierre","family":"Lindenmayer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nina","family":"Schooler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carla M","family":"Canuso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2011,2,7]]},"reference":[{"key":"765_CR1","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1185\/030079906X132613","volume":"22","author":"R Conley","year":"2006","unstructured":"Conley R, Gupta SK, Sathyan G: Clinical spectrum of the osmotic-controlled release oral delivery system (OROS), an advanced oral delivery form. Curr Med Res Opin. 2006, 22: 1879-1892. 10.1185\/030079906X132613.","journal-title":"Curr Med Res Opin"},{"issue":"7","key":"765_CR2","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1177\/0269881109106914","volume":"24","author":"J Berwaerts","year":"2010","unstructured":"Berwaerts J, Cleton A, Rossenu S, Talluri K, Remmerie B, Janssens L, Boom S, Kramer M, Eerdekens M: A comparison of serum prolactin concentrations after administration of paliperidone extended-release and risperidone tablets in patients with schizophrenia. J Psychopharmacol. 2010, 24 (7): 1011-8. 10.1177\/0269881109106914.","journal-title":"J Psychopharmacol"},{"key":"765_CR3","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1055\/s-0029-1202265","volume":"42","author":"J Berwaerts","year":"2009","unstructured":"Berwaerts J, Cleton A, Herben V, van de Vliet I, Chang I, van Hoek P, Eerdekens M: The effects of paroxetine on the pharmacokinetics of paliperidone extended-release tablets. Pharmacopsychiatry. 2009, 42: 158-163. 10.1055\/s-0029-1202265.","journal-title":"Pharmacopsychiatry"},{"issue":"Suppl 3","key":"765_CR4","first-page":"S648","volume":"15","author":"M Vermeir","year":"2005","unstructured":"Vermeir M, Boom S, Naessens I, Talluri K, Eerdekens M: Absorption, metabolism and excretion of a single oral dose of 1 mg paliperidone in a population of five healthy male subjects. Eur Neuropsychopharmacol. 2005, 15 (Suppl 3): S648-","journal-title":"Eur Neuropsychopharmacol"},{"key":"765_CR5","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1176\/ajp.151.6.825","volume":"151","author":"SR Marder","year":"1994","unstructured":"Marder SR, Meibach RC: Risperidone in the treatment of schizophrenia. Am J Psychiatry. 1994, 151: 825-835.","journal-title":"Am J Psychiatry"},{"key":"765_CR6","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1097\/00004714-199302000-00004","volume":"13","author":"G Chouinard","year":"1993","unstructured":"Chouinard G, Jones B, Remington G, Bloom D, Addington D, MacEwan GW, Labelle A, Beauclair L, Arnott W: A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol. 1993, 13: 25-40. 10.1097\/00004714-199302000-00004.","journal-title":"J Clin Psychopharmacol"},{"key":"765_CR7","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.schres.2006.09.012","volume":"90","author":"J Kane","year":"2007","unstructured":"Kane J, Canas F, Kramer M, Ford L, Gassmann-Mayer C, Lim P, Eerdekens M: Treatment of schizophrenia with paliperidone extended-release tablets: a 6-week placebo-controlled trial. Schizophr Res. 2007, 90: 147-161. 10.1016\/j.schres.2006.09.012.","journal-title":"Schizophr Res"},{"key":"765_CR8","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1016\/j.biopsych.2007.01.017","volume":"62","author":"SR Marder","year":"2007","unstructured":"Marder SR, Kramer M, Ford L, Eerdekens E, Lim P, Eerdekens M, Lowy A: Efficacy and safety of paliperidone extended-release tablets: results of a 6-week, randomized, placebo-controlled study. Biol Psychiatry. 2007, 62: 1363-1370. 10.1016\/j.biopsych.2007.01.017.","journal-title":"Biol Psychiatry"},{"key":"765_CR9","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.schres.2007.03.003","volume":"93","author":"M Davidson","year":"2007","unstructured":"Davidson M, Emsley R, Kramer M, Ford L, Pan G, Lim P, Eerdekens M: Efficacy, safety and early response of paliperidone extended-release tablets (paliperidone ER): results of a 6-week, randomized, placebo-controlled study. Schizophr Res. 2007, 93: 117-130. 10.1016\/j.schres.2007.03.003.","journal-title":"Schizophr Res"},{"key":"765_CR10","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1093\/biomet\/70.1.41","volume":"70","author":"PR Rosenbaum","year":"1983","unstructured":"Rosenbaum PR, Rubin DR: The central role of the propensity score in observational studies for causal effects. Biometrika. 1983, 70: 41-55. 10.1093\/biomet\/70.1.41.","journal-title":"Biometrika"},{"key":"765_CR11","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","volume":"13","author":"SR Kay","year":"1987","unstructured":"Kay SR, Fiszbein A, Opler LA: The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987, 13: 261-276.","journal-title":"Schizophr Bull"},{"key":"765_CR12","doi-asserted-by":"publisher","first-page":"538","DOI":"10.4088\/JCP.v58n1205","volume":"58","author":"SR Marder","year":"1997","unstructured":"Marder SR, Davis JM, Chouinard G: The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials. J Clin Psychiatry. 1997, 58: 538-546. 10.4088\/JCP.v58n1205.","journal-title":"J Clin Psychiatry"},{"key":"765_CR13","first-page":"218","volume-title":"ECDEU Assessment Manual for Psychopharmacology. Revised, 1976 edition","author":"W Guy","year":"1976","unstructured":"Guy W: Clinical global impressions. ECDEU Assessment Manual for Psychopharmacology. Revised, 1976 edition. 1976, Rockville, Maryland: U.S. Department of Health and Human Services, 218-222."},{"key":"765_CR14","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1093\/oxfordjournals.aje.a010011","volume":"150","author":"MM Joffe","year":"1999","unstructured":"Joffe MM, Rosenbaum PR: Invited commentary: propensity scores. Am J Epidemiol. 1999, 150: 327-333.","journal-title":"Am J Epidemiol"},{"issue":"1","key":"765_CR15","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1097\/JGP.0b013e31815a3e7a","volume":"16","author":"A Tzimos","year":"2008","unstructured":"Tzimos A, Samokhvalov V, Kramer M, Ford L, Gassmann-Mayer C, Lim P, Eerdekens M: Safety and tolerability of oral paliperidone extended-release tablets in elderly patients with schizophrenia: a double-blind, placebo-controlled study with six-month open-label extension. Am J Geriatr Psychiatry. 2008, 16 (1): 31-43. 10.1097\/JGP.0b013e31815a3e7a.","journal-title":"Am J Geriatr Psychiatry"},{"issue":"5","key":"765_CR16","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1097\/YIC.0b013e3281c55f4f","volume":"22","author":"R Luthringer","year":"2007","unstructured":"Luthringer R, Staner L, Noel N, Muzet M, Gassmann-Mayer C, Talluri K, Cleton A, Eerdekens M, Battisti WP, Palumbo JM: A double-blind, placebo-controlled, randomized study evaluating the effect of paliperidone extended-release tablets on sleep architecture in patients with schizophrenia. Int Clin Psychopharmacol. 2007, 22 (5): 299-308. 10.1097\/YIC.0b013e3281c55f4f.","journal-title":"Int Clin Psychopharmacol"},{"issue":"1","key":"765_CR17","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1097\/JCP.0b013e31802dda4a","volume":"27","author":"M Kramer","year":"2007","unstructured":"Kramer M, Simpson G, Maciulis V, Kushner S, Vijapurkar U, Lim P, Eerdekens M: Paliperidone extended-release tablets for prevention of symptom recurrence in patients with schizophrenia: a randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol. 2007, 27 (1): 6-14. 10.1097\/JCP.0b013e31802dda4a.","journal-title":"J Clin Psychopharmacol"},{"issue":"6","key":"765_CR18","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1176\/appi.ajp.2009.08040613","volume":"166","author":"CM Canuso","year":"2009","unstructured":"Canuso CM, Dirks B, Carothers J, Kosik-Gonzalez C, Bossie CA, Zhu Y, Damaraju CV, Kalali AH, Mahmoud R: Randomized, double-blind, placebo-controlled study of paliperidone extended-release and quetiapine in inpatients with recently exacerbated schizophrenia. Am J Psychiatry. 2009, 166 (6): 691-701. 10.1176\/appi.ajp.2009.08040613.","journal-title":"Am J Psychiatry"},{"issue":"1-3","key":"765_CR19","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/j.schres.2006.03.027","volume":"85","author":"SG Potkin","year":"2006","unstructured":"Potkin SG, Gharabawi GM, Greenspan AJ, Mahmoud R, Kosik-Gonzalez C, Rupnow MF, Bossie CA, Davidson M, Burtea V, Zhu Y, Trivedi JK: A double-blind comparison of risperidone, quetiapine and placebo in patients with schizophrenia experiencing an acute exacerbation requiring hospitalization. Schizophr Res. 2006, 85 (1-3): 254-265. 10.1016\/j.schres.2006.03.027.","journal-title":"Schizophr Res"},{"issue":"3","key":"765_CR20","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s00213-008-1207-7","volume":"200","author":"DE Casey","year":"2008","unstructured":"Casey DE, Sands EE, Heisterberg J, Yang HM: Efficacy and safety of bifeprunox in patients with an acute exacerbation of schizophrenia: results from a randomized, double-blind, placebo-controlled, multicenter, dose-finding study. Psychopharmacology (Berl). 2008, 200 (3): 317-331. 10.1007\/s00213-008-1207-7.","journal-title":"Psychopharmacology (Berl)"},{"issue":"10","key":"765_CR21","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.4088\/JCP.v68n1004","volume":"68","author":"SG Potkin","year":"2007","unstructured":"Potkin SG, Cohen M, Panagides J: Efficacy and tolerability of asenapine in acute schizophrenia: a placebo- and risperidone-controlled trial. J Clin Psychiatry. 2007, 68 (10): 1492-1500. 10.4088\/JCP.v68n1004.","journal-title":"J Clin Psychiatry"},{"issue":"7","key":"765_CR22","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1001\/archpsyc.60.7.681","volume":"60","author":"SG Potkin","year":"2003","unstructured":"Potkin SG, Saha AR, Kujawa MJ, Carson WH, Ali M, Stock E, Stringfellow J, Ingenito G, Marder SR: Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry. 2003, 60 (7): 681-690. 10.1001\/archpsyc.60.7.681.","journal-title":"Arch Gen Psychiatry"},{"issue":"2","key":"765_CR23","first-page":"213","volume":"28","author":"RL Borison","year":"1992","unstructured":"Borison RL, Pathiraja AP, Diamond BI, Meibach RC: Risperidone: clinical safety and efficacy in schizophrenia. Psychopharmacol Bull. 1992, 28 (2): 213-218.","journal-title":"Psychopharmacol Bull"}],"container-title":["BMC Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-244X-11-21\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-244X-11-21.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-244X-11-21","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-244X-11-21.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,1,23]],"date-time":"2019-01-23T01:55:20Z","timestamp":1548208520000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpsychiatry.biomedcentral.com\/articles\/10.1186\/1471-244X-11-21"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,2,7]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,12]]}},"alternative-id":["765"],"URL":"https:\/\/doi.org\/10.1186\/1471-244x-11-21","relation":{},"ISSN":["1471-244X"],"issn-type":[{"value":"1471-244X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,2,7]]},"article-number":"21"}}